5082-74-6

Basic information

• Product Name: 3-Hydroxymethylpyrrolidine
• Synonyms: 3-Pyrrolidinemethanol;pyrrolidin-3-ylmethanol hydrochloride;pyrrolidin-3-ylmethanol(SALTDATA: FREE);pyrrolidin-3-ylMethanol HCl;DL-^b-Prolinol, 97+%;(RS)-3-(Hydroxymethyl)pyrrolidine;(RS)-3-Pyrrolidinemethanol;3-pyrrolidinylmethanol
• CAS NO: 5082-74-6
• Molecular Formula: C₅H₁₁NO
• Molecular Weight: 101.15
• Product Categories: Pyrrolidine series;pharmacetical;Pyrrole&Pyrrolidine&Pyrroline;API intermediates
• Mol File: 5082-74-6.mol

Chemical Properties

• Boiling Point: 165-171℃
• Flash Point: 86℃
• Appearance: /
• Density: 0.979
• Vapor Pressure: 0.339mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: 2-8°C
• PKA: 14.93±0.10(Predicted)
• Water Solubility: Slightly soluble in water
• Sensitive: Hygroscopic
• BRN: 1420904
• CAS DataBase Reference: 3-Hydroxymethylpyrrolidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Hydroxymethylpyrrolidine(5082-74-6)
• EPA Substance Registry System: 3-Hydroxymethylpyrrolidine(5082-74-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5082-74-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Hydroxymethylpyrrolidine is used as a reagent for the preparation of orally active (heterocyclic aminomethyl)pyrazoloquinolines. These compounds are potent PDE10 inhibitors, which are important for the management of schizophrenia. The application reason is that 3-Hydroxymethylpyrrolidine serves as a key building block in the synthesis of these therapeutically relevant molecules, contributing to the development of effective treatments for this mental health disorder.

InChI:InChI=1/C5H11NO/c7-4-5-1-2-6-3-5/h5-7H,1-4H2

Upstream product

• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 5733-86-8 1-benzyl-5-oxopyrrolidine-3-carboxylic acid 
• 1255312-77-6 3-(tert-butyl-diphenylsilanyloxymethyl)-1-(toluene-4-sulfonyl)-pyrrolidine 
• 51535-00-3 methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate 
• 617-52-7 Dimethyl itakonate 
• 35309-35-4 5-oxopyrrolidine-3-carboxylic acid methyl ester 
• 2409-52-1 diethylitaconate 
• 5733-87-9 1-benzyl-3-(ethoxycarbonyl)-5-pyrrolidinone 
• 99735-47-4 (3R)-1-[(R)-1-phenylethyl]-3-(hydroxymethyl)pyrrolidine 
• 192214-04-3 (R)-1-Benzyl-3-benzyloxymethyl-pyrrolidine 
• 303111-43-5 (R)-(+)-1-(phenylmethyl)-3-hydroxymethylpyrrolidine 
• 192214-02-1 β-azidomethyl γ-butyrolactone 
• 99735-45-2 methyl (3R)-1-<(R)-1-phenylethyl>-5-oxo-3-pyrrolidinecarboxylate 
• 138108-72-2 tert-butyl (R)-3-hydroxymethylpyrrolidine-1-carboxylate 

Downstream Products

• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 305329-97-9 3-bromomethylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 479622-36-1 3-iodomethylpyrrolidine-1-carboxylic acid tert-butyl ester 
• 479622-22-5 3-((2S,3R)-2-Benzyloxycarbonyl-4-oxo-azetidin-3-ylmethyl)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 479622-23-6 (2S,3R)-3-(1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-pyrrolidin-3-ylmethyl)-4-oxo-azetidine-2-carboxylic acid benzyl ester 
• 59379-02-1 tert-butyl 3-formylpyrrolidine-1-carboxylate 
• 276872-88-9 (+/-)-3-[4-(4-flourophenylmethyl)piperidinomethyl]-pyrrolidine 
• 1251297-15-0 C₁₂H₁₄N₂O 
• 5731-17-9 1-(Phenylmethyl)-3-pyrrolidinemethanol 
• 1147529-19-8 4-tert-butyl-N-(2-methyl-3-{1-methyl-6-oxo-5-[2-(pyrrolidin-3-ylmethoxy)-pyrimidin-4-ylamino]-1,6-dihydro-pyridazin-3-yl}-phenyl)-benzamide 
• 315718-05-9 benzyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 1355455-26-3 benzyl 3-{[(methylsulfonyl)oxy]methyl}pyrrolidine-1-carboxylate 
• 1355455-35-4 benzyl 3-[(acetylthio)methyl]pyrrolidine-1-carboxylate 

Relevant articles and documents

Discovery of phenylpyrrolidine derivatives as a novel class of retinol binding protein 4 (RBP4) reducers

Retinol-binding protein 4 (RBP4) is a potential drug target for metabolic and ophthalmologic diseases. A high-throughput screening of our compound library has identified a small-molecule RBP4 reducer 7a, as a hit compound. Aiming to provide a suitable too

Preparation method of chiral 3-substituted pyrrolidine derivative

The invention provides a preparation method of a chiral 3-substituted pyrrolidine derivative. The preparation method comprises an intermediate preparation step, a diastereomer mixture preparation step, a chiral separation step and a chiral 3-substituted pyrrolidine derivative synthesis step. According to the invention, through catalytic asymmetric kinetic resolution, a mixture of two diastereoisomers is efficiently converted into a diastereoisomer with a certain single configuration, chiral separation is realized, a key intermediate is obtained with high yield, and a series of chiral 3-substituted pyrrolidine derivatives are synthesized. The whole reaction route is mild in reaction condition, simple and convenient to operate, high in resolution efficiency, high in atom economy, low in costand suitable for industrial scale production.

Method for synthesizing N-Boc-3-pyrrolidine formaldehyde

The invention discloses a method for synthesizing N-Boc-3-pyrrolidine formaldehyde. The method comprises that dimethyl itaconate as a raw material undergoes an intramolecular cyclization reaction to produce methyl 5-oxo-3-pyrrolidine carboxylate, then the methyl 5-oxo-3-pyrrolidine carboxylate undergoes a reduction reaction to produce pyrrolidine-3-methanol, then the pyrrolidine-3-methanol is subjected to Boc protection so that N-Boc-pyrrolidine-3-methanol is obtained, and finally, the N-Boc-pyrrolidine-3-methanol is oxidized to form a final product compound. The method is simple and convenient, has a low cost, content greater than 99%, produces small environmental pollution and is suitable for industrial production.

Concise synthesis of bicyclic aminals by way of catalytic intramolecular C-H amination and evaluation of their reactivity as iminium precursors

The concise synthesis of fused bicyclic aminals by way of intramolecular rhodium-catalyzed C-H amination is reported as well as the evaluation of their reactivity as iminium precursors. In contrast to the well-studied N,O-acetal systems, the aminals synthesized were found to be particularly stable under reaction conditions used for nucleophilic addition.

AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE

Provided herein are pyrrolotriazine compounds for treatment of Aurora kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Iron(III)-catalyzed consecutive aza-cope-mannich cyclization: Synthesis of trans -3,5-dialkyl pyrrolidines and 3,5-dialkyl-2,5-dihydro-1 H-pyrroles

An efficient alkene aza-Cope-Mannich cyclization between 2-hydroxy homoallyl tosylamine and aldehydes in the presence of iron(III) salts to obtain 3-alkyl-1-tosyl pyrrolidines in good yields is described. The process is based on the consecutive generation of a γ-unsaturated iminium ion, 2-azonia-[3,3]-sigmatropic rearrangement, and further intramolecular Mannich reaction. Iron(III) salts are also shown to be excellent catalysts for the new aza-Cope-Mannich cyclization using 2-hydroxy homopropargyl tosylamine.

Disubstituted pyrimidines as Lck inhibitors

We have developed a family of 4-benzimidazolyl-N-piperazinethyl-pyrimidin-2-amines that are subnanomolar inhibitors of Lck. A subset of these Lck inhibitors, with heterocyclic substituents at the benzimidazole C5, are also low-nanomolar inhibitors of cell

Evaluation of structurally diverse neuronal nicotinic receptor ligands for selectivity at the α6* subtype

Direct comparison of pyridine versus pyrimidine substituents on a small but diverse set of ligands indicates that the pyrimidine substitution has the potential to enhance affinity and/or functional activity at α6 subunit-containing neuronal nicotinic rece

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula I and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula I as well as pharmaceutically acceptable compositions comprising compounds of formula I. Compounds of formula I as disclosed herein can be used in a variety of applications including use as antibacterial agents.

QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS

A quinazoline derivative of the formula (I): (A chemical formula should be inserted here - please see paper copy enclosed) Formula I wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.